Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)

$47.65

 0.17 (0.36%)

High$48.67
Low$47.40
Volume788,278
Market Cap$5,950,858,927

07/02/15  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma 06/17/15

Read more

Seattle Genetics and Unum Therapeutics Enter into Strategic Cancer Immunotherapy Collaboration 06/08/15

Read more

Events

UBS Global Healthcare Conference05/19/15 2:00 p.m. ETView eventBank of America Merrill Lynch 2015 Health Care Conference05/14/15 10:40 a.m. PTView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources